Klippel Trenaunay Syndrome Clinical Trials in Cincinnati, Ohio
2 recruitingCincinnati, Ohio
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
PIK3CA MutationVascular MalformationsPIK3CA-Related Overgrowth Spectrum (PROS)+4 more
Relay Therapeutics, Inc.277 enrolled31 locationsNCT06789913
Recruiting
Identification of Biomarkers for Patients with Vascular Anomalies
Vascular AnomalyKlippel Trenaunay SyndromeKaposiform Hemangioendothelioma+4 more
Children's Hospital Medical Center, Cincinnati1,000 enrolled2 locationsNCT03001180